GlassScriptPhysician profile
Marlyn A Newby
NPI 1629091731
$8,975.18
in general payments reported to CMS, 2019-2025
25 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $1,766 · 2023: $2,092 · 2024: $2,473 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,662.33 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,657.62 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Novo Nordisk INC | $1,421.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $788.09 | 2022-2025 | Arexvy, Bexsero, Penmenvy |
| Amgen INC. | $782.42 | 2022-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $575.02 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $397.47 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.03 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $331.35 | 2024-2025 | Voquezna |
| Pfizer INC. | $266.31 | 2022-2024 | |
| Insulet Corporation | $243.39 | 2025 | Omnipod, Omnipod |
| Teva Pharmaceuticals USA, INC. | $243.06 | 2022-2023 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $242.72 | 2022-2023 | Quviviq |
| Abbott Laboratories | $229.95 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $214.70 | 2023 | |
| Novartis Pharmaceuticals Corporation | $188.67 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.39 | 2022-2024 | Lifevest |
| Exact Sciences Corporation | $163.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abiomed | $146.29 | 2024 | Impella |
| Gilead Sciences, INC. | $129.27 | 2023 | Epclusa |
| Mylan Specialty L.P. | $124.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.63 | 2024 | Xarelto |
| Dexcom, INC. | $60.32 | 2022-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $52.03 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.47 | 2022 | |
| Lundbeck LLC | $13.33 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlyn Newby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.